Table 4

Prevalence of pancreatic lesions according to age (n=134 IAR)

Age at first screening
(years)
IAR with any pancreatic lesions (%)IAR with lesions at first screening (%)IAR with lesions during follow-up (%)IAR with significant lesions† detected by screening (%)IAR with significant lesions† at first screening (%)IAR with significant lesions† during follow-up (%)IAR with relevant lesions‡ detected by screening (%)IAR with relevant lesions‡ at first screening (%)IAR with relevant lesions‡ during follow-up (%)
<4016/48 (33%)13 (27%)3 (6%)0/48 (0%)0 (0%)0 (0%)0/48 (0%)0 (0%)0 (0%)
≥40118/205 (57%)76 (37%)42 (20%)6/205 (2.9%)3 (1.45%)3 (1.45%)15/205 (7.3%)6 (2.9%)9 (4.4%)
<4536/98 (37%)26 (27%)10 (10%)0/98 (0%)**0 (0%)0 (0%)0/98 (0%)0 (0%)0 (0%)
≥4598/155 (63%)*63 (41%)35 (22%)6/155 (3.8%)3 (1.9%)3 (1.9%)15/155 (9.7%)6 (3.9%)9 (5.8%)
<5067/152 (44%)46 (30%)21 (14%)0/152 (0%)**0 (0%)0 (0%)2/152 (1.3%)0 (0%)2 (1.3%)
≥5067/101 (66%)43 (42%)24 (24%)6/101 (6%)3 (3%)3 (3%)13/101 (12.9%)***6 (5.9%)7 (7%)
<5586/183 (47%)56 (31%)30 (16%)3/183 (1.6%)1 (0.5%)2 (1.1%)7/183 (3.8%)1 (0.5%)6 (3.3%)
≥5548/70 (68%)33 (47%)15 (21%)3/70 (4.2%)2 (2.8%)1 (1.4%)8/70 (11.4%)5 (7.1%)3 (4.3%)
<60107/217 (49%)70 (32%)37 (17%)3/217 (1.4%)1 (0.45%)2 (0.95%)9/217 (4.1%)1 (0.4%)8 (3.7%)
≥6027/36 (75%)19 (53%)8 (22%)3/36 (8.3%)2 (5.6%)1 (2.7%)6/36 (16.6%)5 (13.9%)1 (2.7%)
Total with lesions134/253 (52.9%)89 (35%)45 (18%)6/253 (2.4%)3 (1.2%)3 (1.2%)15/253 (5.9%)6 (2.3%)9 (3.6%)
  • *p=0.0001; **p<0.001; ***p=0.0004.

  • †Includes PDAC, PanIN3, high-grade IPMN.

  • ‡Potentially relevant lesions: includes PDAC, multifocal PanIN2/3 lesions with/without low/moderate dysplastic BD-IPMN or AFL, pNET.

  • AFL, atypical flat lesion; BD, branch duct; IAR, individuals at risk; PanIN, pancreatic intraepithelial neoplasia; IPMN, intraductal papillary mucinous neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.